Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559819 · ClinicalTrials.gov registry record · Phase 3
Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving
A Phase 3 study of Impairment and Driving, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00559819: Completed Phase 3 study of Impairment and Driving, sponsored by Rush University Medical Center.
NCT00559819 is a Phase 3 study of Impairment and Driving that has completed, run by Rush University Medical Center. The registered enrollment target is 32 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00559819, a Phase 3 study of Impairment and Driving, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study will validate and determine sensitivity of our new driving simulator, created to evaluate driving ability in a related study to show similar driving performance between patients on chronic opioid treatment and a control group. Although the commercial version of the simulator has been validated for certain populations and certain measures, these require re-calibration for our own clinical study. The investigators propose a prospective randomized clinical trial to evaluate driving skills under alcohol consumption using a driving simulator. Two groups of study subjects will be utilized, with the majority (80%) receiving alcohol and placebo at different times. A smaller set of study subjects (20%) will be given placebo on both trials to evaluate learning effects and placebo blinding effectiveness. Each group will take the driving test at three time points: once as a baseline at the beginning of the study, once after the 1st dosing of the placebo and again after dosing two of the alcohol or placebo beverage. This information will allow us to evaluate driving ability under other potentially impairing conditions such as opioid usage.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Alcohol
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-02 |
| Est. Completion | 2022-07 |
| Phase | Phase 3 |
What the finished NCT00559819 record still lists
NCT00559819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Impairment appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00559819 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00559819 about?
NCT00559819 is a clinical study titled "Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving". The proposed study will validate and determine sensitivity of our new driving simulator, created to evaluate driving ability in a related study to show similar driving performance between patients on chronic opioid treatment and a control group. Although the commercial version of the simulator has b...
What is the current status of trial NCT00559819?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2008-02. Estimated completion is 2022-07.
What conditions does trial NCT00559819 study?
This clinical trial studies the following conditions: Impairment, Driving, Intoxication, Alcohol Impaired Driving.
What interventions are being tested in trial NCT00559819?
The interventions under investigation include: placebo (DRUG), Alcohol (DRUG).
Who is sponsoring clinical trial NCT00559819?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00559819 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00559819's enrollment target sits among peer trials
32 1909th of 2000 higher than 87 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia